Predictive circulating biomarkers of the response to anti-PD-1 immunotherapy in advanced HER2 negative breast cancer

Yuhan Wei; Hewei Ge; Yalong Qi; Cheng Zeng; Xiaoying Sun; Hongnan Mo; Fei Ma

doi:10.1002/ctm2.70255

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (3) : e70255 DOI: 10.1002/ctm2.70255

RESEARCH ARTICLE

Predictive circulating biomarkers of the response to anti-PD-1 immunotherapy in advanced HER2 negative breast cancer

Author information +

History +

PDF

Abstract

	•CD39+ Tregs in peripheral blood are associated with poor response to anti-PD-1 immunotherapy in advanced breast cancer.
	•Higher frequencies of CCR2+ monocyte-derived dendritic cells correlate with better immunotherapy outcomes.
	•A predictive model based on CD39+ Tregs and monocyte-derived dendritic cells effectively distinguishes patient progression-free survival.
	•Peripheral blood biomarkers offer a non-invasive approach to guide immunotherapy choices.

Keywords

breast cancer / CyTOF / immunotherapy / PD-1 / peripheral blood mononuclear cell / predictive biomarkers / systemic immunity

Cite this article

Download citation ▾

Yuhan Wei,Hewei Ge,Yalong Qi,Cheng Zeng,Xiaoying Sun,Hongnan Mo,Fei Ma. Predictive circulating biomarkers of the response to anti-PD-1 immunotherapy in advanced HER2 negative breast cancer. Clinical and Translational Medicine, 2025, 15(3): e70255 DOI:10.1002/ctm2.70255

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.